While the CRoFT will be administratively housed at RPCI, this is an equal partnership with the University of Rochester Medical Center, which provides valuable complementary expertise and experience in team science. Through the years, key members of the CRoFT team have developed numerous partnerships to meet the common goal of trying to develop the best science to improve public health. Key examples include:

  1. O’Connor has worked with Dorothy Hatsukami’s group in partnership on a U19 cooperative agreement to assess methods and measures for evaluating modified risk tobacco products; this has evolved into a second P01 examining the issue of cigarette filter ventilation, product standards, and adenocarcinoma.
  2. O’Connor and Goniewicz are collaborating with Mike Cummings’s group and the ITC Project on a P01 to examine the impact of different regulatory regimes for ENDS across countries (US, UK, Canada, Australia) on use patterns and product design and emissions.
  3. Goniewicz is Co-I on two separate large randomized controlled trials to determine the clinical efficacy of ENDS in smoking cessation (PIs: Hayden McRobbie, UK, and Matthew Carpenter, USA).
  4. Hyland, Bansal-Travers, and Goniewicz are heavily involved in the PATH study, a multiyear cohort survey supported by FDA and NIDA, involving numerous government and academic partner institutions.
  5. The RPCI group has successfully translated science to policy respect to secondhand smoke exposure, with the widespread adoption by public health practitioners of the TSI Sidepak for measuring particulate matter levels and demonstrating the effects of smokefree policy.
  6. RPCI and UR have a history of collaboration with regard to smoking cessation and tobacco control, including the NY State Smokers Quitline. UR was a subcontractor for delivering proactive calls and website interventions (subcontracts were later restricted on the parent contract). In 2003, a Lake Ontario Tobacco Control research consortium was convened by Dr. Ossip, which led to a number of research collaborations. RPCI/UR personnel sit on NYSDOH Bureau of Tobacco Control Advisory Board (Bansal-Travers, McIntosh).
  7. Ossip and McIntosh lead ongoing NIH-supported international capacity building efforts for tobacco control research, initially centered in the Dominican Republic, and later extended to five Latin American and Caribbean countries for development of information communication technology (ICT) projects addressing maternal health issues.
  8. Rahman, Ossip, and McIntosh have an ongoing collaboration on waterpipe and ENDS-nicotine research funded by NIDA and NHLBI.
  9. UR holds a Clinical and Translational Science Institute (CTSI) award, which develops, demonstrates and disseminates methods and approaches to advance translational research, by providing education and training, supporting transdisciplinary teams, improving quality and efficiency, and engaging community stakeholders. Drs. Steele, Li, and Ossip are key contributors to the CTSI.
  10. UR is a NYS designated Center of Excellence in Data Science (Dr. Steele is MPI on this award), which seeks to bring researchers, engineers, and computer scientists together with the necessary resources to empower multidisciplinary collaborations and increase the pool of well-trained data scientists.